HRP20120963T1 - PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI - Google Patents

PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI Download PDF

Info

Publication number
HRP20120963T1
HRP20120963T1 HRP20120963TT HRP20120963T HRP20120963T1 HR P20120963 T1 HRP20120963 T1 HR P20120963T1 HR P20120963T T HRP20120963T T HR P20120963TT HR P20120963 T HRP20120963 T HR P20120963T HR P20120963 T1 HRP20120963 T1 HR P20120963T1
Authority
HR
Croatia
Prior art keywords
group
refers
ring
heterocyclyl
aryl
Prior art date
Application number
HRP20120963TT
Other languages
English (en)
Croatian (hr)
Inventor
Marc Geoffrey Hummersone
Sylvie Gomez
Keith Allan Menear
Graeme Cameron Murray Smith
Karine Malagu
Heather Mary Ellen Duggan
Xiao-Ling Fan Cockcroft
Gesine Johanna Hermann
Original Assignee
Kudos Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37533284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120963(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0524047A external-priority patent/GB0524047D0/en
Application filed by Kudos Pharmaceuticals Ltd filed Critical Kudos Pharmaceuticals Ltd
Publication of HRP20120963T1 publication Critical patent/HRP20120963T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HRP20120963TT 2005-11-22 2006-11-20 PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI HRP20120963T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73890205P 2005-11-22 2005-11-22
GB0524047A GB0524047D0 (en) 2005-11-25 2005-11-25 Compounds
US82330806P 2006-08-23 2006-08-23
US82330906P 2006-08-23 2006-08-23
PCT/GB2006/004327 WO2007060404A1 (en) 2005-11-22 2006-11-20 PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS

Publications (1)

Publication Number Publication Date
HRP20120963T1 true HRP20120963T1 (hr) 2012-12-31

Family

ID=37533284

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120963TT HRP20120963T1 (hr) 2005-11-22 2006-11-20 PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI

Country Status (15)

Country Link
US (1) US20080194546A1 (enExample)
EP (1) EP1954699B1 (enExample)
JP (1) JP5161102B2 (enExample)
KR (1) KR101464384B1 (enExample)
AR (1) AR057626A1 (enExample)
AU (1) AU2006318948B2 (enExample)
CA (1) CA2628920C (enExample)
EC (1) ECSP088536A (enExample)
HR (1) HRP20120963T1 (enExample)
IL (1) IL191196A (enExample)
NO (1) NO341055B1 (enExample)
PL (1) PL1954699T3 (enExample)
TW (1) TWI452047B (enExample)
UY (1) UY29938A1 (enExample)
WO (1) WO2007060404A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2441869C2 (ru) * 2005-12-21 2012-02-10 Эбботт Лэборетриз Противовирусные соединения
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
UA96304C2 (en) * 2006-08-23 2011-10-25 Кудос Фармасьютикалз Лимитед 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
AU2007287430B2 (en) 2006-08-23 2011-07-21 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
WO2008133753A2 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
EP2217590A4 (en) * 2007-09-17 2011-12-14 Glaxosmithkline Llc Pyridopyrimidine derivatives as PI3-kinase inhibitors
BRPI0818426A2 (pt) * 2007-10-15 2017-06-13 Astrazeneca Ab produto de combinação, uso de um produto de combinação, e, método para tratar câncer
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
CA2715181A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
MY172107A (en) 2008-06-20 2019-11-14 Astrazeneca Ab Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pyrimidines
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
KR20110046514A (ko) * 2008-07-31 2011-05-04 제넨테크, 인크. 피리미딘 화합물, 조성물 및 사용 방법
EP2349275B1 (en) * 2008-10-31 2017-03-08 Novartis AG Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor.
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
RU2012125152A (ru) 2009-11-18 2013-12-27 Новартис Аг Способы и композиции, предназначенные для лечения солидных опухолей и других злокачественных новообразований
WO2011067356A2 (en) 2009-12-03 2011-06-09 Novartis Ag Polymorphs of a mek inhibitor
WO2011067348A2 (en) 2009-12-03 2011-06-09 Novartis Ag Mek inhibitor salts and solvates thereof
UA110697C2 (uk) 2010-02-03 2016-02-10 Сігнал Фармасьютікалз, Елелсі ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK
US8440651B2 (en) * 2010-02-22 2013-05-14 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use
CN102821759A (zh) 2010-03-30 2012-12-12 诺华有限公司 用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
US20130035336A1 (en) 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
CA2803055A1 (en) 2010-06-25 2011-12-29 Novartis Ag Heteroaryl compounds and compositions as protein kinase inhibitors
WO2012099581A1 (en) 2011-01-19 2012-07-26 Takeda Pharmaceutical Company Limited Dihydrofuropyrimidine compounds
EP2739751A1 (en) 2011-08-03 2014-06-11 Signal Pharmaceuticals, LLC Identification of gene expression profile as a predictive biomarker for lkb1 status
CN102911172A (zh) * 2011-08-04 2013-02-06 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
CN103374021B (zh) * 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CN105793254B (zh) 2012-11-29 2020-10-23 默克专利有限公司 氮杂喹唑啉羧酰胺衍生物
KR102242505B1 (ko) 2013-04-17 2021-04-20 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
AU2014254057A1 (en) 2013-04-17 2015-11-05 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
ES2944478T3 (es) 2013-04-17 2023-06-21 Signal Pharm Llc 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
WO2018144791A1 (en) * 2017-02-03 2018-08-09 Millennium Pharmaceuticals, Inc. Combination of vps34 inhibitors and mtor inhibitors
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
RU2771201C2 (ru) * 2017-11-06 2022-04-28 Медшайн Дискавери Инк. ПИРИДОПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ВЫПОЛНЯЮЩИЕ ФУНКЦИЮ ДВОЙНЫХ ИНГИБИТОРОВ mTORC 1/2
WO2021133509A1 (en) * 2019-12-27 2021-07-01 Angex Pharmaceutical, Inc. Heterocyclic compounds as mtor inhibitors
MX2022008627A (es) 2020-01-13 2022-11-08 Verge Analytics Inc Pirazolo-pirimidinas sustituidas y usos de las mismas.
WO2021247859A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Pyridopyrimidines and methods of their use
US20230357233A1 (en) * 2020-08-26 2023-11-09 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof
CN117088898A (zh) * 2022-05-13 2023-11-21 中国药科大学 稠环嘧啶类化合物及其制备方法、药物组合物和应用
WO2024057013A1 (en) * 2022-09-12 2024-03-21 Exscientia Ai Limited Nlrp3 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) * 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) * 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
DK1481970T3 (da) * 1999-09-07 2006-07-31 Syngenta Participations Ag Nye herbicider
CN1186324C (zh) * 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
GB0428475D0 (en) * 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders

Also Published As

Publication number Publication date
US20080194546A1 (en) 2008-08-14
PL1954699T3 (pl) 2013-01-31
CA2628920C (en) 2015-12-29
UY29938A1 (es) 2007-06-29
HK1124039A1 (en) 2009-07-03
TWI452047B (zh) 2014-09-11
NO20082101L (no) 2008-08-15
AU2006318948A1 (en) 2007-05-31
AU2006318948B2 (en) 2011-02-24
WO2007060404A1 (en) 2007-05-31
EP1954699B1 (en) 2012-09-19
EP1954699A1 (en) 2008-08-13
ECSP088536A (es) 2008-07-30
JP5161102B2 (ja) 2013-03-13
CA2628920A1 (en) 2007-05-31
IL191196A (en) 2016-02-29
TW200738706A (en) 2007-10-16
NO341055B1 (no) 2017-08-14
AR057626A1 (es) 2007-12-05
KR20080070079A (ko) 2008-07-29
JP2009516727A (ja) 2009-04-23
KR101464384B1 (ko) 2014-11-21

Similar Documents

Publication Publication Date Title
HRP20120963T1 (hr) PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI
RU2502730C2 (ru) Сульфонамидные соединения и их применение
MA29136B1 (fr) Agents de potentialisation de recepteurs du glutamate
AR075139A1 (es) Compuestos biciclicos para la reduccion de la produccion de beta-amiloide
CO6150162A2 (es) Pirrolopirimidinas para composiciones farmaceuticas
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
BR112015015275A8 (pt) composto heterocíclico substituído por halogênio, antagonista do receptor de lpa, composição farmacêutica e uso
MX391567B (es) Agentes de imagenología nuevos para tomografía de emisión de positrones (pet) sustituidos con deuterio y su aplicación farmacológica.
UY30300A1 (es) Compuestos triarílicos y sus derivados
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
MX391445B (es) Formas cristalinas de 3-(imidazol[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
PA8795301A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
BRPI0408591A (pt) derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
HRP20141046T1 (hr) Tricikliäśki spoj i njegova farmaceutska uporaba
PE20090655A1 (es) Derivados de 2-aza-biciclo[2.2.2]octano para prevencion o tratamiento de psicosis
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren